{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:45:41Z","timestamp":1781624741069,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clml.2025.01.008","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:29:40Z","timestamp":1737484180000},"page":"e383-e392.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-1307","authenticated-orcid":false,"given":"Danny","family":"Luan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neela","family":"Easwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0698","authenticated-orcid":false,"given":"Brian","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.01.008_bib0001","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the Rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.008_bib0002","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.008_bib0003","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.008_bib0004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.01.008_bib0005","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/bloodadvances.2021005715","article-title":"Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes","volume":"6","author":"Castellino","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.008_bib0006","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.008_bib0007","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.008_bib0008","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam Constantine","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.008_bib0009","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to Bortezomib: pphase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.clml.2025.01.008_bib0010","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter Phase II study of Bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"JCO"},{"key":"10.1016\/j.clml.2025.01.008_bib0011","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.008_bib0012","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle\u2013Cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.01.008_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00942-3","article-title":"Evolving treatment patterns and improved outcomes in relapsed\/refractory mantle cell lymphoma: a prospective cohort study","volume":"13","author":"Bock","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.01.008_bib0014","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: eenhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.clml.2025.01.008_bib0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jgo.2012.12.005","article-title":"A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes","volume":"4","author":"Davidoff","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clml.2025.01.008_bib0016","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.29290","article-title":"Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma","volume":"121","author":"Williams","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.01.008_bib0017","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1080\/10428194.2021.1889540","article-title":"Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset","volume":"62","author":"Luan","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.01.008_bib0018","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clml.2025.01.008_bib0019","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clml.2025.01.008_bib0020","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non\u2013small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.01.008_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00155","article-title":"An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non\u2013Small-cell lung cancer","volume":"3","author":"Stewart","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clml.2025.01.008_bib0022","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang Michael","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.008_bib0023","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/bloodadvances.2023011152","article-title":"Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study","volume":"8","author":"Tivey","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.008_bib0024","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/bloodadvances.2023009804","article-title":"Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed\/refractory mantle cell lymphoma","volume":"7","author":"Villa","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.008_bib0026","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3324\/haematol.2022.282252","article-title":"Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis","volume":"108","author":"Di","year":"2023","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:26:20Z","timestamp":1747686380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2152265025000199"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}